Shares of CARSGEN-B (ASX: 02171) have surged more than 6%. At the time of writing, the stock is up 5.94% to HK$16.42, with a turnover of HK$32.63 million.
On July 15, the company announced that preliminary positive results from a Chinese investigator-initiated trial for Kailimei® (suradencel, product code: CT041, an autologous CAR-T cell therapy candidate targeting Claudin18.2) have been accepted for poster presentation at the 2026 European Society for Medical Oncology (ESMO) Congress. The trial, designated CT041-CG4010 (NCT06857786), is evaluating the therapy as consolidation treatment following adjuvant therapy for gastric/gastroesophageal junction adenocarcinoma.
The abstract will be published on the ESMO website on Monday, October 19, 2026, at 00:05 Central European Summer Time.
The company stated that as of July 15, since patient enrollment began in May 2025, none of the participants treated with Kailimei® in the CT041-CG4010 study have experienced post-operative recurrence or metastasis of gastric cancer.
Kailimei® is a first-in-class global autologous CAR-T cell therapy targeting the Claudin18.2 protein for the treatment of Claudin18.2-positive solid tumors. It received marketing approval from China's National Medical Products Administration in June 2026 for the treatment of Claudin18.2-positive, HER2-negative, advanced gastric/gastroesophageal junction adenocarcinoma in patients who have failed at least two prior lines of therapy, making it the world's first approved CAR-T cell therapy for a solid tumor.
Comments